about
[Brivaracetam for add-on treatment in focal epilepsy].Lacosamide in status epilepticus: Systematic review of current evidence.Sphingosine-1-phosphate receptor inhibition prevents denervation-induced dendritic atrophyFunctional and structural properties of dentate granule cells with hilar basal dendrites in mouse entorhino-hippocampal slice cultures.The efficacy of lacosamide as monotherapy and adjunctive therapy in focal epilepsy and its use in status epilepticus: clinical trial evidence and experiencePerampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.Treatment of refractory and super-refractory status epilepticus with brivaracetam: A cohort study from two German university hospitals.Eslicarbazepine acetate in epilepsies with focal and secondary generalised seizures: systematic review of current evidence.Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany.Repetitive magnetic stimulation induces plasticity of excitatory postsynapses on proximal dendrites of cultured mouse CA1 pyramidal neurons.Eslicarbazepine acetate as a therapeutic option in a patient with carbamazepine-induced rash and HLA-A*31:01.Invasive EEG-electrodes in presurgical evaluation of epilepsies: Systematic analysis of implantation-, video-EEG-monitoring- and explantation-related complications, and review of literatureQuality of life and correlating factors in children, adolescents with epilepsy, and their caregivers: A cross-sectional multicenter study from GermanyTools for your stroke team: adapting crew-resource management for acute stroke careFirst clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre studyRecent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel as broad-spectrum antiseizure drugs for the treatment of epilepsies and status epilepticusGeneral Trends in Prices and Prescription Patterns of Anticonvulsants in Germany between 2000 and 2017: Analysis of National and Cohort-Based Data
P50
Q30390285-8368F22B-2710-4FFE-9EBB-0E00281CF31EQ30399934-1908CAF7-4F12-49FF-ABA1-4D9B51F035BAQ35976992-A6A89202-F679-410E-B103-67D5A6AA6360Q36381162-4AD336E3-7F8E-4505-A20E-E5BC9050D845Q37722778-759513BF-A8D9-48D0-A100-AE9FD92751C5Q38599106-72930B97-ECB8-4F12-BC70-145C3DA0B4B6Q38739649-6C86E572-2C61-43F5-8618-B3CC932C7295Q38828381-5D1B5034-5D5C-4850-B72A-C169047B3B31Q47235722-872DAD2B-3B76-4A3A-A8B3-6AA631A27358Q47733662-D5B8ECC3-6FE5-4BFC-A6ED-E4941444167EQ48613274-CC41B1EA-8DFD-4813-AA33-C0D9B87A76E6Q51087419-26B0184F-5B8F-432A-9EAE-1D542EC082A3Q57926665-0C9E637D-95FE-4534-AD67-C14B782F4F53Q90031972-5A318726-2FB9-4D5C-99C9-696230AADFA6Q90878951-E08248C0-6BD1-4C3C-87DD-C6D28C4EC4D6Q91129313-5D74E7D2-0981-4CA7-ABE0-520B74A1BAAFQ91541991-5CD8C00D-796B-4DED-91BB-62D3ECE3986CQ92506218-74D2EFC4-C534-47B6-A02A-1534F60DFEAC
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Laurent M Willems
@ast
Laurent M Willems
@en
Laurent M Willems
@es
Laurent M Willems
@nl
type
label
Laurent M Willems
@ast
Laurent M Willems
@en
Laurent M Willems
@es
Laurent M Willems
@nl
prefLabel
Laurent M Willems
@ast
Laurent M Willems
@en
Laurent M Willems
@es
Laurent M Willems
@nl
P106
P214
527145857894523021257
P31
P496
0000-0001-8226-1674
P734
P7859
viaf-527145857894523021257